| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
|
N Engl J Med
|
2008
|
9.20
|
|
2
|
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.
|
Nat Genet
|
2009
|
6.99
|
|
3
|
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.
|
Nature
|
2008
|
6.24
|
|
4
|
Physical activity and survival after colorectal cancer diagnosis.
|
J Clin Oncol
|
2006
|
5.22
|
|
5
|
Subgroup-specific structural variation across 1,000 medulloblastoma genomes.
|
Nature
|
2012
|
4.13
|
|
6
|
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
|
Cancer Res
|
2009
|
3.77
|
|
7
|
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.
|
Proc Natl Acad Sci U S A
|
2003
|
3.72
|
|
8
|
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
2.63
|
|
9
|
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.
|
Genes Dev
|
2008
|
2.61
|
|
10
|
Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
|
Cancer Res
|
2009
|
2.54
|
|
11
|
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
|
J Pathol
|
2011
|
2.27
|
|
12
|
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
|
Lancet Oncol
|
2009
|
2.23
|
|
13
|
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
|
J Clin Oncol
|
2008
|
2.04
|
|
14
|
An in vivo patient-derived model of endogenous IDH1-mutant glioma.
|
Neuro Oncol
|
2011
|
1.70
|
|
15
|
Consensus guidelines for the management and treatment of neuroendocrine tumors.
|
Pancreas
|
2013
|
1.65
|
|
16
|
Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.
|
Endocr Relat Cancer
|
2013
|
1.62
|
|
17
|
Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.
|
Proc Natl Acad Sci U S A
|
2011
|
1.58
|
|
18
|
Cytogenetic prognostication within medulloblastoma subgroups.
|
J Clin Oncol
|
2014
|
1.56
|
|
19
|
Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein.
|
J Immunol
|
2005
|
1.43
|
|
20
|
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
|
Clin Cancer Res
|
2006
|
1.42
|
|
21
|
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.
|
PLoS Genet
|
2010
|
1.40
|
|
22
|
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
|
Acta Neuropathol
|
2013
|
1.35
|
|
23
|
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
|
Proc Natl Acad Sci U S A
|
2013
|
1.33
|
|
24
|
A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes.
|
Hum Mol Genet
|
2004
|
1.33
|
|
25
|
Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events.
|
Brain Pathol
|
2010
|
1.32
|
|
26
|
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity.
|
Acta Neuropathol
|
2014
|
1.28
|
|
27
|
Prediagnostic plasma folate and the risk of death in patients with colorectal cancer.
|
J Clin Oncol
|
2008
|
1.14
|
|
28
|
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.
|
J Mol Diagn
|
2011
|
1.11
|
|
29
|
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
1.11
|
|
30
|
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
|
J Natl Cancer Inst
|
2011
|
1.06
|
|
31
|
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
|
PLoS One
|
2012
|
1.05
|
|
32
|
Migration from a mitogenic niche promotes cell-cycle exit.
|
J Neurosci
|
2005
|
1.04
|
|
33
|
Lactate dehydrogenase A silencing in IDH mutant gliomas.
|
Neuro Oncol
|
2013
|
1.04
|
|
34
|
Family history and survival after colorectal cancer diagnosis.
|
Cancer
|
2008
|
1.04
|
|
35
|
Prognostic significance of MTOR pathway component expression in neuroendocrine tumors.
|
J Clin Oncol
|
2013
|
1.02
|
|
36
|
RAS/ERK signaling controls proneural genetic programs in cortical development and gliomagenesis.
|
J Neurosci
|
2014
|
0.98
|
|
37
|
A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes.
|
Neuro Oncol
|
2013
|
0.96
|
|
38
|
Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer.
|
Cancer Res
|
2010
|
0.92
|
|
39
|
PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.92
|
|
40
|
DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma.
|
Ann Neurol
|
2012
|
0.91
|
|
41
|
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.
|
J Clin Oncol
|
2010
|
0.89
|
|
42
|
Heparan sulfate proteoglycans containing a glypican 5 core and 2-O-sulfo-iduronic acid function as Sonic Hedgehog co-receptors to promote proliferation.
|
J Biol Chem
|
2013
|
0.88
|
|
43
|
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.
|
Invest New Drugs
|
2013
|
0.88
|
|
44
|
GSK3 temporally regulates neurogenin 2 proneural activity in the neocortex.
|
J Neurosci
|
2012
|
0.86
|
|
45
|
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.
|
Oncologist
|
2013
|
0.83
|
|
46
|
Neurog1 and Neurog2 control two waves of neuronal differentiation in the piriform cortex.
|
J Neurosci
|
2014
|
0.82
|
|
47
|
Post-chemotherapy maturation in supratentorial primitive neuroectodermal tumors.
|
Brain Pathol
|
2013
|
0.82
|
|
48
|
IDH mutation detection in formalin-fixed paraffin-embedded gliomas using multiplex PCR and single-base extension.
|
Brain Pathol
|
2012
|
0.76
|
|
49
|
Sustained response to weekly vinblastine in 2 children with pilomyxoid astrocytoma associated with diencephalic syndrome.
|
J Pediatr Hematol Oncol
|
2013
|
0.75
|
|
50
|
Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.
|
Pancreas
|
2016
|
0.75
|
|
51
|
Reply to A. Koumarianou et al and J. Hadoux et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
52
|
Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index.
|
Pancreas
|
2017
|
0.75
|
|
53
|
Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma.
|
J Neurooncol
|
2006
|
0.75
|
|
54
|
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
|
Pancreas
|
2017
|
0.75
|
|
55
|
EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency.
|
Am J Hematol
|
2002
|
0.75
|